Published in Autophagy on April 01, 2012
Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem (2012) 1.79
Autophagy and neurodegeneration. J Clin Invest (2015) 1.24
Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci (2014) 1.15
Cysteine reactivity distinguishes redox sensing by the heat-inducible and constitutive forms of heat shock protein 70. Chem Biol (2012) 1.10
Successful therapies for Alzheimer's disease: why so many in animal models and none in humans? Front Pharmacol (2014) 1.10
Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. Biol Psychiatry (2013) 1.03
Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease. Front Neurol (2013) 1.03
Hsp70 protein complexes as drug targets. Curr Pharm Des (2013) 1.00
Tau phosphorylation affects its axonal transport and degradation. Neurobiol Aging (2013) 1.00
Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. ACS Chem Neurosci (2013) 1.00
Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice. PLoS One (2012) 0.98
The human HSP70 family of chaperones: where do we stand? Cell Stress Chaperones (2016) 0.95
Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation. J Biol Chem (2013) 0.95
Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum Mol Genet (2014) 0.94
Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. ACS Chem Biol (2012) 0.94
Tau as a therapeutic target in neurodegenerative disease. Pharmacol Ther (2012) 0.92
The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy. PLoS One (2015) 0.89
Signaling pathway cross talk in Alzheimer's disease. Cell Commun Signal (2014) 0.89
Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuropathol Commun (2015) 0.87
Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice. J Neurosci (2014) 0.86
Methylene blue treatment delays progression of perfusion-diffusion mismatch to infarct in permanent ischemic stroke. Brain Res (2014) 0.86
Treatment implications of C9ORF72. Alzheimers Res Ther (2012) 0.85
Involvement of interleukin-1β in the autophagic process of microglia: relevance to Alzheimer's disease. J Neuroinflammation (2013) 0.84
Methylene blue induces macroautophagy through 5' adenosine monophosphate-activated protein kinase pathway to protect neurons from serum deprivation. Front Cell Neurosci (2013) 0.84
Methylene Blue Reduces Acute Cerebral Ischemic Injury via the Induction of Mitophagy. Mol Med (2015) 0.82
Methylene Blue Inhibits Caspases by Oxidation of the Catalytic Cysteine. Sci Rep (2015) 0.81
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. Biomed Res Int (2016) 0.81
Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy. Neurosci Lett (2014) 0.81
Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav Pharmacol (2015) 0.81
The Effects of Methylene Blue on Autophagy and Apoptosis in MRI-Defined Normal Tissue, Ischemic Penumbra and Ischemic Core. PLoS One (2015) 0.80
Promoting autophagic clearance: viable therapeutic targets in Alzheimer's disease. Neurotherapeutics (2015) 0.80
Potential synergy between tau aggregation inhibitors and tau chaperone modulators. Alzheimers Res Ther (2013) 0.80
Roles of tau protein in health and disease. Acta Neuropathol (2017) 0.80
Autophagy in Alzheimer's disease. Rev Neurosci (2015) 0.78
Methylene blue exerts a neuroprotective effect against traumatic brain injury by promoting autophagy and inhibiting microglial activation. Mol Med Rep (2015) 0.78
Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models. Mol Neurodegener (2014) 0.78
Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease. Neurol Sci (2016) 0.77
Tau Biology and Tau-Directed Therapies for Alzheimer's Disease. Drugs (2016) 0.77
Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment. Sci Rep (2016) 0.77
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol (2015) 0.77
Methylene blue promotes quiescence of rat neural progenitor cells. Front Cell Neurosci (2014) 0.77
Nontoxic singlet oxygen generator as a therapeutic candidate for treating tauopathies. Sci Rep (2015) 0.77
Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice. J Biol Chem (2014) 0.76
Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimers Dement (2016) 0.76
Synthesis, stereochemical analysis, and derivatization of myricanol provide new probes that promote autophagic tau clearance. ACS Chem Biol (2015) 0.76
Intrinsic Tau Acetylation Is Coupled to Auto-Proteolytic Tau Fragmentation. PLoS One (2016) 0.76
Autophagy and Alzheimer's Disease. Cell Mol Neurobiol (2016) 0.76
A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy. Sci Rep (2017) 0.75
Methylene blue treatment in experimental ischemic stroke: a mini review. Brain Circ (2016) 0.75
TFEB Overexpression in the P301S Model of Tauopathy Mitigates Increased PHF1 Levels and Lipofuscin Puncta and Rescues Memory Deficits. eNeuro (2016) 0.75
Modulation of Autophagy as a Therapeutic Target for Alzheimer's Disease. Postdoc J (2013) 0.75
Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots. Prog Neurobiol (2015) 0.75
Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease. CNS Neurol Disord Drug Targets (2014) 0.75
Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy. Mol Neurodegener (2016) 0.75
PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo. PLoS One (2015) 0.75
Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle. NPJ Aging Mech Dis (2015) 0.75
Methylene blue and its analogues as antidepressant compounds. Metab Brain Dis (2017) 0.75
Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer's disease. Cell Mol Life Sci (2017) 0.75
p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol (2005) 18.23
In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell (2003) 17.55
Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell (2007) 14.63
Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy (2007) 11.74
Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science (2004) 8.71
Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol (2007) 8.29
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol (2007) 8.07
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG. Mol Biol Cell (2008) 7.32
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A (1990) 4.26
Consequences of the selective blockage of chaperone-mediated autophagy. Proc Natl Acad Sci U S A (2006) 3.87
Small molecule regulators of autophagy identified by an image-based high-throughput screen. Proc Natl Acad Sci U S A (2007) 3.37
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther (2005) 3.27
Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci (2008) 3.19
Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol (2007) 3.18
Two ubiquitin-like conjugation systems essential for autophagy. Semin Cell Dev Biol (2004) 3.04
Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci (2009) 2.82
Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci (2007) 2.55
Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem (2001) 2.32
Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem (2004) 2.11
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A (1996) 2.11
Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci (2009) 2.05
Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry (2000) 1.93
Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem (2005) 1.79
Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener (2010) 1.68
Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain (2009) 1.66
A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. Proc Natl Acad Sci U S A (2010) 1.65
Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur J Neurosci (2008) 1.54
An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A (2006) 1.52
Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol (2011) 1.46
Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry (2007) 1.44
Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J (2007) 1.44
Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem (2011) 1.41
Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci U S A (2006) 1.33
Inhibition of hsp70 by methylene blue affects signaling protein function and ubiquitination and modulates polyglutamine protein degradation. J Biol Chem (2010) 1.29
GSK-3beta promotes cell survival by modulating Bif-1-dependent autophagy and cell death. J Cell Sci (2010) 1.12
Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J Nutr Health Aging (2009) 1.08
Methylene blue provides behavioral and metabolic neuroprotection against optic neuropathy. Neurotox Res (2009) 1.04
Removal of pattern-breaking sequences in microtubule binding repeats produces instantaneous tau aggregation and toxicity. J Biol Chem (2006) 1.04
Organotypic slice cultures from transgenic mice as disease model systems. J Mol Neurosci (2002) 0.98
Generation of tau aggregates and clearance by autophagy in an inducible cell model of tauopathy. Neurodegener Dis (2010) 0.94
Methylene blue prevents methylmalonate-induced seizures and oxidative damage in rat striatum. Neurochem Int (2006) 0.92
Striatal neuroprotection with methylene blue. Neuroscience (2009) 0.90
Alz-50/Gallyas-positive lysosome-like intraneuronal granules in Alzheimer's disease and control brains. Neurosci Lett (1998) 0.88
Neurofibrillary tangles may interfere with Smad 2/3 signaling in neurons. J Neuropathol Exp Neurol (2007) 0.87
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature (2006) 11.59
Potential therapeutic applications of autophagy. Nat Rev Drug Discov (2007) 8.56
Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell (2010) 5.09
Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J Neurosci (2008) 4.63
Trans-synaptic spread of tau pathology in vivo. PLoS One (2012) 4.53
A field of myocardial-endocardial NFAT signaling underlies heart valve morphogenesis. Cell (2004) 3.71
Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci (2007) 3.52
Synthetic multivalent ligands as probes of signal transduction. Angew Chem Int Ed Engl (2006) 3.29
Solution conformation of wild-type E. coli Hsp70 (DnaK) chaperone complexed with ADP and substrate. Proc Natl Acad Sci U S A (2009) 2.77
Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci (2007) 2.68
Heat shock protein 70 (hsp70) as an emerging drug target. J Med Chem (2010) 2.21
Conditional protein alleles using knockin mice and a chemical inducer of dimerization. Mol Cell (2003) 2.20
Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc Natl Acad Sci U S A (2008) 2.09
Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci (2009) 2.05
Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. J Neurosci (2013) 2.04
Chemical screens against a reconstituted multiprotein complex: myricetin blocks DnaJ regulation of DnaK through an allosteric mechanism. Chem Biol (2011) 1.89
Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J Biol Chem (2006) 1.86
Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem (2012) 1.79
The D1 dopamine receptor is constitutively phosphorylated by G protein-coupled receptor kinase 4. Mol Pharmacol (2005) 1.75
Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener (2010) 1.68
High-throughput screen for small molecules that modulate the ATPase activity of the molecular chaperone DnaK. Anal Biochem (2007) 1.65
Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. Chem Biol (2006) 1.65
Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron (2008) 1.59
Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci (2007) 1.58
The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules. J Neurosci (2010) 1.57
The phospholipase D1 pathway modulates macroautophagy. Nat Commun (2010) 1.56
Allostery in the Hsp70 chaperone proteins. Top Curr Chem (2013) 1.52
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res (2008) 1.51
Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem (2011) 1.51
Pharmacological targeting of the Hsp70 chaperone. Curr Top Med Chem (2009) 1.51
Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol (2013) 1.51
Allosteric drugs: the interaction of antitumor compound MKT-077 with human Hsp70 chaperones. J Mol Biol (2011) 1.49
Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits. J Neurosci (2010) 1.49
Control of multivalent interactions by binding epitope density. J Am Chem Soc (2002) 1.46
Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci U S A (2013) 1.45
Α-synuclein misfolding and Parkinson's disease. Biochim Biophys Acta (2011) 1.43
Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J Neurosci (2010) 1.42
LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation (2010) 1.40
Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J (2009) 1.40
Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat Chem Biol (2012) 1.37
Ube2w and ataxin-3 coordinately regulate the ubiquitin ligase CHIP. Mol Cell (2011) 1.37
Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des (2007) 1.36
FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol Metab (2011) 1.34
Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis (2003) 1.32
Inhibition of hsp70 by methylene blue affects signaling protein function and ubiquitination and modulates polyglutamine protein degradation. J Biol Chem (2010) 1.29
Binding of a small molecule at a protein-protein interface regulates the chaperone activity of hsp70-hsp40. ACS Chem Biol (2010) 1.28
The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep (2010) 1.28
Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci (2008) 1.28
Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol (2009) 1.27
Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Am J Pathol (2009) 1.24
Facilitating Akt clearance via manipulation of Hsp70 activity and levels. J Biol Chem (2009) 1.22
Fine-tuning multiprotein complexes using small molecules. ACS Chem Biol (2012) 1.21
Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions. Chem Biol Drug Des (2013) 1.21
Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Rev Mol Med (2012) 1.18
Identification of dihydropyridines that reduce cellular tau levels. Chem Commun (Camb) (2010) 1.17
Aging enhances classical activation but mitigates alternative activation in the central nervous system. Neurobiol Aging (2013) 1.16
Anesthesia-induced hyperphosphorylation detaches 3-repeat tau from microtubules without affecting their stability in vivo. J Neurosci (2008) 1.15
Mutagenesis reveals the complex relationships between ATPase rate and the chaperone activities of Escherichia coli heat shock protein 70 (Hsp70/DnaK). J Biol Chem (2010) 1.15
Phosphorylation dynamics regulate Hsp27-mediated rescue of neuronal plasticity deficits in tau transgenic mice. J Neurosci (2010) 1.13
Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy. FASEB J (2005) 1.13
Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest (2013) 1.12
The role of phosphorylation in D1 dopamine receptor desensitization: evidence for a novel mechanism of arrestin association. J Biol Chem (2003) 1.12
Rescue of degradation-prone mutants of the FK506-rapamycin binding (FRB) protein with chemical ligands. Chembiochem (2007) 1.10
Insight into amyloid structure using chemical probes. Chem Biol Drug Des (2011) 1.10
A poke in the eye: inhibiting HIV-1 protease through its flap-recognition pocket. Biopolymers (2008) 1.10
Cysteine reactivity distinguishes redox sensing by the heat-inducible and constitutive forms of heat shock protein 70. Chem Biol (2012) 1.10
Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu Rev Pharmacol Toxicol (2014) 1.09
A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. Neurobiol Dis (2008) 1.09
Identification of small molecules that modify the protein folding activity of heat shock protein 70. Anal Biochem (2007) 1.08
Imbalance of Hsp70 family variants fosters tau accumulation. FASEB J (2012) 1.07
Hsc70 rapidly engages tau after microtubule destabilization. J Biol Chem (2010) 1.06
Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. Biol Psychiatry (2013) 1.03
Synthesis and applications of end-labeled neoglycopolymers. Org Lett (2002) 1.03
A new anti-depressive strategy for the elderly: ablation of FKBP5/FKBP51. PLoS One (2011) 1.02
CSAR data set release 2012: ligands, affinities, complexes, and docking decoys. J Chem Inf Model (2013) 1.02
Binding of human nucleotide exchange factors to heat shock protein 70 (Hsp70) generates functionally distinct complexes in vitro. J Biol Chem (2013) 1.01
Chemical control over protein-protein interactions: beyond inhibitors. Comb Chem High Throughput Screen (2007) 1.01
Hsp70 protein complexes as drug targets. Curr Pharm Des (2013) 1.00
Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. ACS Chem Neurosci (2013) 1.00
Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents. ACS Med Chem Lett (2013) 1.00